We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+42.47%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$354M
AUM Growth
+$83.8M
Cap. Flow
+$17.9M
Cap. Flow %
5.04%
Top 10 Hldgs %
61.1%
Holding
35
New
–
Increased
14
Reduced
4
Closed
9

Top Buys

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$8.63M
2
GNMK
GenMark Diagnostics, Inc
GNMK
+$8.47M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.11M
4
EVH icon
Evolent Health
EVH
+$5.67M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$5.26M

Top Sells

Rank Stock Value
1
EPZM
Epizyme, Inc
EPZM
+$7.85M
2
GILD icon
Gilead Sciences
GILD
+$5.31M
3
AMRS
Amyris Inc.
AMRS
+$1.59M
4
TSRO
TESARO, Inc.
TSRO
+$1.18M
5
SAGE
Sage Therapeutics
SAGE
+$1.18M

Sector Composition

Rank Sector Weight
1 Healthcare 85.27%
2 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
$33.2M 9.36%
360,000
– –
MYOK
2
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$24M 6.78%
560,000
+165,000
+42% +$5.26M
ALNY icon
3
Alnylam Pharmaceuticals
ALNY
$29.2B
$23.5M 6.64%
200,000
+95,000
+90% +$8.11M
SGMO
4
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$21M 5.93%
1,400,000
– –
BPMC
5
DELISTED
Blueprint Medicines
BPMC
$20.8M 5.86%
298,000
+23,000
+8% +$1.23M
BLUE
6
DELISTED
bluebird bio
BLUE
$19.9M 5.62%
11,194
+6,176
+123% +$8.63M
FMI
7
DELISTED
Foundation Medicine, Inc.
FMI
$19.3M 5.45%
480,000
– –
KITE
8
DELISTED
Kite Pharma, Inc.
KITE
$19.1M 5.38%
106,000
+16,000
+18% +$2.23M
ONCE
9
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$18.7M 5.27%
209,474
+39,474
+23% +$3M
AGIO icon
10
Agios Pharmaceuticals
AGIO
$1.84B
$17M 4.81%
255,000
– –
VYGR icon
11
Voyager Therapeutics
VYGR
$179M
$16.8M 4.74%
815,000
+75,000
+10% +$846K
SAGE
12
DELISTED
Sage Therapeutics
SAGE
$15M 4.22%
240,000
-15,000
-6% -$1.18M
GNMK
13
DELISTED
GenMark Diagnostics, Inc
GNMK
$14.4M 4.08%
1,500,000
+815,000
+119% +$8.47M
EVH icon
14
Evolent Health
EVH
$359M
$14.2M 4%
795,000
+275,000
+53% +$5.67M
GBT
15
DELISTED
Global Blood Therapeutics, Inc.
GBT
$11.8M 3.33%
380,000
+165,000
+77% +$4.64M
BOLD
16
DELISTED
Audentes Therapeutics, Inc
BOLD
$11.2M 3.16%
400,000
– –
CLVS
17
DELISTED
Clovis Oncology, Inc.
CLVS
$10.5M 2.97%
127,500
-2,500
-2% -$198K
CDXS icon
18
Codexis
CDXS
$158M
$9.81M 2.77%
1,475,000
+285,000
+24% +$1.58M
ILMN icon
19
Illumina
ILMN
$30.2B
$8.77M 2.47%
45,232
+12,850
+40% +$2.39M
JNCE
20
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$6.23M 1.76%
399,825
+239,825
+150% +$3.39M
TSRO
21
DELISTED
TESARO, Inc.
TSRO
$4.97M 1.4%
38,500
-9,500
-20% -$1.18M
SYRS
22
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$3.77M 1.06%
25,622
+7,408
+41% +$1.39M
CTMX icon
23
CytomX Therapeutics
CTMX
$686M
$3.23M 0.91%
177,500
– –
EDIT icon
24
Editas Medicine
EDIT
$399M
$3.2M 0.9%
133,333
– –
FATE icon
25
Fate Therapeutics
FATE
$294M
$2.18M 0.62%
550,000
– –
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q3 2017 Portfolio in Review

As of Q3 2017, Casdin Capital held 35 positions worth $354M, up 31% from $270M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Casdin Capital deployed $17.9M of net new capital in Q3 2017, adding to 14 existing holdings.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 82% a quarter earlier, followed by Materials.

On the sell side, the largest reduction was TESARO, Inc., an estimated $1.18M trimmed.

  • Casdin Capital added most to bluebird bio in Q3 2017, an estimated $8.63M increase.
  • Casdin Capital's biggest Q3 2017 reduction was TESARO, Inc., cutting an estimated $1.18M.
  • Casdin Capital fully exited Epizyme, Inc in Q3 2017, selling an estimated $7.85M.
  • Casdin Capital's ten largest holdings make up 61% of its $354M portfolio in Q3 2017.
  • Casdin Capital opened 0 new positions and closed 9 in Q3 2017.
  • Casdin Capital's portfolio value rose 31% quarter-over-quarter to $354M.

Based on Casdin Capital's 13F filing for Q3 2017, filed 14 Nov 2017.